Lupin enters into licensing agreement with Alvion to market cardiometabolic drugs in the Southeast Asia region
Mumbai / Malaysia / Vietnam, 5 April 2022 — Global pharma major Lupin Limited (Lupin) announced today that it has entered into a licensing agreement with Alvion Pharmaceuticals S.M.S.A. (Alvion) to commercialize medicines for cardiometabolic diseases in the Southeast Asia region.
Lupin is committed to providing new, affordable treatment options to healthcare providers and patients. By commercializing cardiometabolic drugs in the Southeast Asian region, Lupin will play a significant role in improving the quality of healthcare and access to medicines.
“Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across Southeast Asia with quality, cost-effective alternatives for patients and the healthcare system. Both companies have a solid track record of developing and launching products, and this agreement will further cement Lupin as a formidable pharmaceutical company in the region. We look forward to expanding our partnership with Alvion over the coming years.”
Gabriel Georgy — Regional Head, Southeast Asia, Lupin
“Alvion is delighted to partner with Lupin for its important proprietaries and looks forward to launching the products in the Southeast Asia region. Being a leader in value-added medicines, Alvion shall support Lupin’s activities, aiming to position both companies at the forefront for both molecules.”
John Bouros — Chief Executive Officer, Alvion Pharmaceuticals
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and the Middle East. The company enjoys a leadership position in the cardiovascular, anti-diabetic and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions, and invested 9.6% of its revenue in research and development in FY21.
Lupin has 15 manufacturing sites, 7 research centres and more than 20,000 professionals working globally, and has been consistently recognized as a “Great Place to Work” in the Biotechnology & Pharmaceuticals sector. For more information, please visit lupin.com.
BSE: 500257 · NSE: LUPIN · Reuters: LUPIN.BO · Bloomberg: LPCIN
About Alvion
Alvion Pharmaceuticals S.M.S.A. (Alvion), Athens, Greece, is an international pharmaceutical company focusing on the development of added-value generic medicines in various blockbuster therapeutic categories including but not limited to cardiovascular, diabetes, urinary and central nervous system. With sales in more than 50 countries, Alvion licenses its products to the leading pharmaceutical companies across the world. For more information, please visit alvionpharma.com.
Media Contacts
Shweta Munjal
Vice President & Global Head — Corporate Communications, Lupin
shwetamunjal@lupin.com
Marina Ioannidou
Corporate Communications Head, Alvion
m.ioannidou@alvionpharma.com